Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00GXL
|
|||
| Former ID |
DIB016884
|
|||
| Drug Name |
PBT-2
|
|||
| Synonyms |
AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Huntington disease [ICD-11: 8A01.10; ICD-10: G10] | Phase 2 | [2] | ||
| Company |
Prana biotechnology
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H12Cl2N2O
|
|||
| Canonical SMILES |
CN(C)CC1=NC2=C(C=C1)C(=CC(=C2O)Cl)Cl
|
|||
| InChI |
1S/C12H12Cl2N2O/c1-16(2)6-7-3-4-8-9(13)5-10(14)12(17)11(8)15-7/h3-5,17H,6H2,1-2H3
|
|||
| InChIKey |
YZPOQCQXOSEMAZ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 747408-78-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Microtubule-associated protein tau (MAPT) | Target Info | Modulator | [3], [4] |
| KEGG Pathway | MAPK signaling pathway | |||
| Alzheimer's disease | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| EGFR1 Signaling Pathway | ||||
| Pathway Interaction Database | LPA receptor mediated events | |||
| Reelin signaling pathway | ||||
| Reactome | Caspase-mediated cleavage of cytoskeletal proteins | |||
| WikiPathways | Notch Signaling Pathway | |||
| IL-2 Signaling Pathway | ||||
| MAPK Signaling Pathway | ||||
| Copper homeostasis | ||||
| Kit receptor signaling pathway | ||||
| BDNF signaling pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Alzheimers Disease | ||||
| Regulation of Microtubule Cytoskeleton | ||||
| Apoptotic execution phase | ||||
| IL-5 Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01590888) Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16. | |||
| REF 4 | Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.